key: cord-0734136-fx6rgwfh
authors: Shi, Li; Xu, Jie; Xiao, Wenwei; Wang, Ying; Jin, Yuefei; Chen, Shuaiyin; Duan, Guangcai; Yang, Haiyan; Wang, Yadong
title: Asthma in patients with coronavirus disease 2019: a systematic review and meta-analysis
date: 2021-02-18
journal: Ann Allergy Asthma Immunol
DOI: 10.1016/j.anai.2021.02.013
sha: 75b76db4d5e3436c9227c77147ca50fb8da69ce8
doc_id: 734136
cord_uid: fx6rgwfh

BACKGROUND: It is unclear if there is the influence of asthma on contracting COVID-19, or having worse outcomes from COVID-19 disease. OBJECTIVE: To explore the prevalence of asthma in COVID-19 patients and the relationship between asthma and COVID-19 patients with poor outcomes. METHODS: The pooled prevalence of asthma in COVID-19 patients and corresponding 95% confidence interval (CI) were estimated. The pooled effect size (ES) was used to evaluate the association between asthma and COVID-19 patients with poor outcomes. RESULTS: The pooled prevalence of asthma in COVID-19 patients worldwide was 8.3% (95% CI 7.6-9.0%) based on 116 articles (119 studies) with 403,392 cases. The pooled ES based on unadjusted effect estimates showed that asthma was not associated with the reduced risk of poor outcomes in COVID-19 patients (ES 0.91, 95% CI 0.78-1.06). Similarly, the pooled ES based on unadjusted effect estimates revealed that asthma was not associated with the reduced risk of mortality in COVID19 patients (ES 0.88, 95% CI 0.73-1.05). However, the pooled ES based on adjusted effect estimates indicated that asthma was significantly associated with the reduced risk of mortality in COVID-19 patients (ES 0.80, 95% CI 0.74-0.86). CONCLUSION: The pooled prevalence of asthma in COVID-19 patients was similar to that in the general population, and asthma might be an independent protective factor for the death of COVID-19 patients, which suggests that we should pay high attention to COVID-19 patients with asthma and take locally tailored interventions and treatment. Further well-designed studies with large sample sizes are required to verify our findings.

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), a novel 4 betacoronavirus, caused the coronavirus disease 2019 (COVID- 19) , which has posed 5 huge challenges to global public health. To date (data as at 28 September 2020), over 6 32.7 million confirmed cases and more than 991,000 deaths have been reported 7 worldwide. 1 The continuous increasing of confirmed cases and related clinical studies 8 has led to a greater understanding of COVID-19. Many comorbidities have been 9 identified as risk factors for COVID-19 patients with poor outcomes, such as diabetes, 10 hypertension, malignancies, cardiovascular diseases (CVDs), and chronic obstructive 11 pulmonary disease (COPD), which can help clinicians identify patients with poor 12 prognosis at an early stage and thus contribute to the control and prevention of 13 COVID-19. 2 

Asthma, a common chronic disease, can be exacerbated by viral respiratory 15 infections, 3 which has recently attracted considerable attention of researchers focused 16 on COVID-19. Nevertheless, the prevalence of asthma in COVID-19 patients and the 17 association between asthma and COVID-19 patients with poor outcomes remains 18 highly controversial. Zhang et al. 4 identified particularly low prevalence of asthma 19 (0.3%) among 289 patients with COVID-19 in Wuhan, which was significantly lower 20 than local population asthma prevalence (4.2%). 5 Conversely, Latz et al. 6 pointed out 21 that asthmatic patients accounted for up to 26 .9% of included COVID-19 patients in 22 J o u r n a l P r e -p r o o f the state of Massachusetts, US. In addition, the studies conducted by Yehia et al. 7 and 23 Siso-Almirall et al. 8 indicated that asthma was not a significant predictive comorbidity 24 for death of COVID-19 patients. However, Almazeedi et al. 9 reported that asthma was 25 significantly associated with an increased risk of death in COVID-19 patients, 26 whereas Hernandez-Galdamez et al. 10 and Santos et al. 11 found that asthma was a 27 protective factor of death. 28 In view of the above, a systematic and quantitative meta-analysis to explore the 29 prevalence of asthma in COVID-19 patients and the relationship between asthma and 30 COVID-19 patients with poor outcomes would be of paramount importance. 31 

Search strategy and selection criteria 33 We conducted a systematical search of PubMed, Web of Science, and EMBASE 34 databases to recognize eligible studies published from inception to September 18, 35 2020 using the following terms and keywords: "asthma" or "respiratory diseases" or 36 "comorbidities" or "clinical" AND "novel coronavirus" or "nCoV" or "2019-nCoV" 37 or "COVID-19" or "coronavirus" or "severe acute respiratory syndrome coronavirus 2" 38 or "SARS-CoV-2". The literature search was not restricted by language. The reference 39 lists of all pertinent studies and reviews were sifted to identify other eligible studies. 40 In addition, when publications with overlapping data were found, only the articles 41 with the larger sample size or more complete analysis were included. EndNote Reviews and Meta-Analysis (PRISMA) statement (eTable 1). 12 

Inclusion criteria were the following: (1) all patients enrolled in articles were 46 diagnosed with COVID-19; (2) articles clearly reported the number of asthmatic 47 COVID-19 patients. 48 Exclusion criteria were as follows: (1) abstracts, reviews, meta-analysis, and errata; 49 (2) studies with the sample size fewer than 100 patients; (3) articles with overlapping 50 data; (4) articles reporting unclear prevalence of asthma in COVID-19 patients.

Data extraction and quality assessment 52 Two researchers (Li Shi and Wenwei Xiao) respectively reviewed all literatures 53 according to the inclusion and exclusion criteria and excerpted the following 54 information: author, location or country, study design, total number of patients, age, 55 gender, settings, the number of asthmatic COVID-19 patients, and the number of 56 asthma patients with poor outcomes (e.g. patients diagnosed with severe or critical 57 COVID-19, or admitted to intensive care unit (ICU), or required mechanical 58 ventilation (MV), or died). Any conflicts were resolved by group discussion. 59 The quality of the enrolled studies was evaluated by two independent researchers 60 using the Agency for Healthcare Research and Quality (AHRQ) score checklist. 13 The 61 quality of the studies was graded as low (0-3), moderate (4-7), or high (8-11) 62 according to the corresponding range of scores. 63 Statistical analysis 64 All statistical analyses were carried out using R (version 3.6.3) and Stata (version SE 65 12.1). A meta-analysis of the included studies was done with the metaprop command 66 J o u r n a l P r e -p r o o f in R to calculate the pooled prevalence of asthma in COVID-19 patients. Furthermore, 67 a meta-analysis of the included studies was also done with the metan command in 68 STATA to evaluate the risk of having poor outcomes in patients with COVID-19 and 69 asthma co-infection. Considering the influence of various factors such as gender, age, 70 and other comorbidities on the risk of mortality in COVID-19 patients, 2 the pooled 71 effect size (ES) and corresponding 95% confidence interval (CI) were calculated on 72 the basis of the studies reporting the adjusted effect estimates. The chi-squared-based 73 Q test (represented as χ² and P values) and I 2 statistic were applied to assess the 74 heterogeneity among studies. 14 If I 2 < 50% or P > 0.05, we utilized the fixed-effects 75 model. Otherwise, the random-effects model was chosen. Considering the obvious 76 heterogeneity of our analysis, subgroup and meta-regression analyses were conducted 77 to investigate possible factors caused heterogeneity. The factors that we investigated 78 were sample size, study design, region, settings, and quality score. Publication bias 79 was examined by Begg's test and Egger's test. 15 

Study selection 83 Initially, 49,026 records were retrieved by our search strategy. By deleting duplicates 84 of original retrieved articles, 28,553 related articles were obtained. 209 articles that 85 reported the prevalence of asthma in COVID-19 patients were yielded after reading 86 the titles and abstracts. Subsequently, 44 articles were excluded because of a sample 87 size less than 100, 47 articles were eliminated due to the potential duplicate patients, 88 J o u r n a l P r e -p r o o f and two articles were removed because they reported unclear prevalence of asthma in 89 COVID-19 patients (eTable 2). Ultimately, 116 articles (119 studies) 4, 6-11, 17-125 with 90 403,392 COVID-19 patients passed multiple screening (Fig 1) . 91 Study characteristics 92 All patients in enrolled articles were diagnosed with COVID-19 (eTable 3). The main 93 characteristics of the enrolled studies are shown in Table 1 . The included studies were 94 from different countries and regions around the world, of which 64 from the Americas, 95 28 from Europe, 22 from Asia, one from the Middle East, and four from other 96 countries. In term of the study design, 101 were retrospective studies, seven were 97 prospective studies, five were cross-sectional studies, and three each were 98 ambispective studies and randomized controlled trials (RCTs). Through the qualitative 99 assessment, 47 studies were of high quality, 71 studies were of moderate quality, and 100 the remaining one study was of low quality (eTable 4).

The pooled prevalence of asthma in COVID-19 patients 102 The estimated prevalence of asthma in COVID-19 patients ranged from 0.3% to 103 26.9%. By combining 119 studies (a total of 403,392 patients) reporting the data of 104 asthma patients with COVID-19, the pooled prevalence of asthma in COVID-19 105 patients was 8.3% (95% CI 7.6-9.0%; random-effects model), and heterogeneity was 106 obvious (χ² = 9311.76, P < 0.01; I² = 98.7%) (Fig 2) . Therefore, we conducted 107 subgroup and meta-regression analyses to explore the possible factors caused 108 heterogeneity according to sample size, study design, region, settings, and quality 109 score (Table 2 and eFigs 1-5). The pooled prevalence of asthma among COVID-19 110 J o u r n a l P r e -p r o o f patients was 3.3% (95% CI 1.9-4.6%; χ² = 712.56, P < 0.01; I² = 97.1%) in Asia, 11.1% 111 (95% CI 9.9-12.3%; χ² = 5466.42, P < 0.01; I² = 98.8%) in the Americas, 7.0% (95% 112 CI 5.0-9.0%; χ² = 1608.20, P < 0.01; I² = 98.3%) in Europe, and 9.4% (95% CI 113 6.2-12.5%; χ² = 18.82, P < 0.01; I² = 84.1%) in other countries. Only one study was 114 completed in the Middle East and the prevalence of asthma in COVID-19 patients was 115 2.0% (95% CI 1.8-2.1%). The results of univariate meta-regression showed that 116 region (P < 0.001) might be a factor caused heterogeneity, whereas no significant 117 differences were observed in sample size (P = 0.131), settings (P = 0.337), study 118 design (P = 0.936), or quality score (P = 0.610).

The association between the asthma and the poor outcomes of COVID-19 Our quantitative meta-analysis suggested that the pooled prevalence of asthma in 145 COVID-19 patients worldwide was 8.3%, which was contained in a range (4.3-8.6%) 146 of the global prevalence rates of asthma. 126 The pooled prevalence of asthma in 147 COVID-19 patients worldwide (8.3%) that was more similar to the global prevalence 148 of wheezing (8.6%) using the least stringent definition of asthma. 126 Considering the 149 obvious heterogeneity of our analysis, we subsequently performed subgroup analysis 150 and meta-regression according to sample size, study design, region, settings, and 151 quality score. The univariate meta-regression implied that region (P < 0.001) might be Control and Prevention (CDC) pointed out that adult self-reported asthma prevalence 160 was 9.2%. 128 All of these evidences seemed to indicate that the prevalence of asthma 161 among COVID-19 patients in different regions and countries seemed to be similar to 162 the prevalence of asthma in the general population. 163 To explore the relationship between asthma and COVID-19 patients with poor patients, although the corresponding 95% CI crossed 1 (ES 0.91, 95% CI 0.78-1.06). 169 We hypothesized that the different poor outcomes reported in the included articles and 

World Health Organization

Risk factors for mortality in patients with Coronavirus disease 2019 (COVID-19) infection: a systematic review and meta-analysis of observational studies

Viruses and bacteria in acute asthma exacerbations--a GA(2) LEN-DARE systematic review

Clinical, radiological, and laboratory characteristics and risk factors for severity and mortality of 289 hospitalized COVID-19 patients

Prevalence, risk factors, and management of asthma in China: a national cross-sectional study

Blood type and outcomes in patients with COVID-19

Association of Race With Mortality Among Patients Hospitalized With Coronavirus Disease 2019 (COVID-19) at 92 US Hospitals

Prognostic factors in Spanish COVID-19 patients: A case series from Barcelona

Characteristics, risk factors and outcomes among the first consecutive 1096 patients diagnosed with COVID-19 in Kuwait

Increased Risk of Hospitalization and Death in Patients with COVID-19 and Pre-existing Noncommunicable Diseases and Modifiable Risk Factors in Mexico

Survival and predictors of deaths of patients hospitalised due to COVID-19 from a retrospective and multicentre cohort study in Brazil

Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement

Measuring inconsistency in meta-analyses

Systems to rate the strength of scientific evidence

Operating characteristics of a rank correlation test for publication bias

Bias in meta-analysis detected by a simple, graphical test

The Association of Renin-Angiotensin-Aldosterone System Inhibitors With Outcomes Among a

Predominantly Ethnic Minority Patient Population Hospitalized With COVID-19: The Bronx Experience

Neurological manifestations in 404 COVID-19 patients in Washington State

Association of Initial Viral Load in Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Patients with Outcome and Symptoms

Treatment with hydroxychloroquine, azithromycin, and combination in patients hospitalized with COVID-19

Comparison of mortality risk in patients with cirrhosis and COVID-19 compared with patients with cirrhosis alone and COVID-19 alone: multicentre matched cohort

Asthma in COVID-19 Hospitalizations: An Overestimated Risk Factor?

Characterization of Critically Ill COVID-19 Patients at a Brooklyn Safety-Net Hospital

Neurological complications in a predominantly African American sample of COVID-19 predict worse outcomes during hospitalization

Prevalence and characterization of asthma in hospitalized and nonhospitalized patients with COVID-19

Epidemiology, clinical course, and outcomes of critically ill adults with COVID-19 in New York City: a prospective cohort study

Treatment and preliminary outcomes of 150 acute care patients with COVID-19 in a rural health system in the Dakotas

The relationship between diabetes and clinical outcomes in COVID-19: a single-center retrospective analysis

Hospitalization Rates and Characteristics of Patients Hospitalized with Laboratory-Confirmed Coronavirus Disease

Patient Trajectories Among Persons Hospitalized for COVID-19 : A Cohort Study

Clinical characteristics, outcomes and prognosticators in adult patients hospitalized with COVID-19

Clinical characteristics and predictors of mortality in African-Americans with COVID-19 from an inner-city community teaching hospital in New York

Clinical Course and Factors Associated With Hospitalization and Critical Illness Among COVID-19 Patients in

Obesity and COVID-19 in New York City: A Retrospective Cohort Study

Factors Associated With Death in Critically Ill Patients With Coronavirus Disease 2019 in the US

COVID-19 in Patients with Inflammatory Arthritis: A Prospective Study on the Effects of Comorbidities and DMARDs on Clinical Outcomes. Arthritis Rheumatol

Development and validation of a model for individualized prediction of hospitalization risk in 4,536 patients with COVID-19

Effect of Systemic Glucocorticoids on Mortality or Mechanical Ventilation in Patients With COVID-19

Predictors of Outcomes of COVID-19 in Patients with Chronic Liver Disease: US Multi-center Study

Risk Factors for COVID-19-associated hospitalization: COVID-19-Associated Hospitalization Surveillance Network and Behavioral Risk Factor Surveillance System

Clinical comorbidities, characteristics, and outcomes of mechanically ventilated patients in the State of Michigan with SARS-CoV-2 pneumonia

COVID-19 outcomes of patients with gynecologic cancer

Asthma among hospitalized patients with COVID-19 and related outcomes

Routine Venous Thromboembolism Prophylaxis May Be Inadequate in the Hypercoagulable State of Severe Coronavirus Disease

Outcomes of Hydroxychloroquine Usage in United States Veterans Hospitalized with COVID-19

Impact of SARS-CoV-2 Viral Load on Risk of Intubation and Mortality Among Hospitalized Patients with Coronavirus Disease

Early clinical and sociodemographic experience with patients hospitalized with COVID-19 at a large American healthcare system

Risk Factors for Mortality in Patients with COVID-19 in New York City

ICU Patients With COVID-19. Chest

COVID-19 patients in a tertiary US hospital: Assessment of clinical course and predictors of the disease severity

Clinical Outcomes in Critically Ill Coronavirus Disease 2019 Patients: A Unique New York City Public Hospital Experience

The impact of obesity on COVID-19 complications: a retrospective cohort study

Outcomes of patients with end-stage kidney disease hospitalized with COVID-19

Clinical and Epidemiological Characteristics of Patients Diagnosed with Covid-19 in a Tertiary Care Center in Mexico City: A Prospective Cohort Study

Increased Serum Aminotransferase Activity and Clinical Outcomes in Coronavirus Disease

Presenting Characteristics, Comorbidities, and Outcomes Among 5700 Patients Hospitalized With COVID-19 in the New York City Area

Determinants of COVID-19 disease severity in patients with cancer

Characterization of Patients with COVID-19 Admitted to a Community Hospital of East Harlem

Demographics, comorbidities and outcomes in hospitalized Covid-19 patients in rural southwest Georgia

Clinical Characteristics and Outcomes Based on Race of Hospitalized Patients With COVID-19 in a New Orleans Cohort

Cohort of Four Thousand Four Hundred Four Persons Under Investigation for COVID-19 in a New York Hospital and Predictors of ICU Care and Ventilation

Early administration of interleukin-6 inhibitors for patients with severe COVID-19 disease is associated with decreased intubation, reduced mortality, and increased discharge

Hydroxychloroquine in Nonhospitalized Adults With Early COVID-19: A Randomized Trial

Impaired glucose metabolism in patients with diabetes, prediabetes, and obesity is associated with severe COVID-19

Tocilizumab for treatment of mechanically ventilated patients with COVID-19

Circulatory System Diseases in Patients with COVID-19: Description of Clinical and Epidemiological Profile of 197 Deaths

Clinical Characteristics and Morbidity Associated With Coronavirus Disease 2019 in a Series of Patients in Metropolitan Detroit

Obesity and Mortality Among Patients Diagnosed With COVID-19: Results From an Integrated Health Care Organization

Characteristics of Adult Outpatients and Inpatients with COVID-19 -11 Academic Medical Centers

Mortality Rates in a Diverse Cohort of Mechanically Ventilated Patients With Novel Coronavirus in the Urban Midwest

Empiric Antibacterial Therapy and Community-onset Bacterial Co-infection in Patients Hospitalized with COVID-19: A Multi-Hospital Cohort Study

The Minimal Effect of Zinc on the Survival of Hospitalized Patients With COVID-19: An Observational Study

Prediction model and risk scores of ICU admission and mortality in COVID-19

Epidemiology, outcomes and associated factors of COVID-19 RT-PCR confirmed cases in the

Clinical characteristics of COVID-19 in Saudi Arabia: A national retrospective study

Clinical Profiles, Characteristics, and Outcomes of the First 100 Admitted COVID-19 Patients in Pakistan: A Single-Center Retrospective Study in a Tertiary Care Hospital of Karachi

Association of hypertension and antihypertensive treatment with COVID-19 mortality: a retrospective observational study

A novel risk score to predict diagnosis with coronavirus disease 2019 (COVID-19) in suspected patients: A retrospective, multicenter, and observational study

Risk factors for severity and mortality in adult COVID-19 inpatients in Wuhan

High neutrophil-to-lymphocyte ratio associated with progression to critical illness in older patients with COVID-19: a multicenter retrospective study

Analysis of clinical features and early warning signs in patients with severe COVID-19: A retrospective cohort study

Assessing risk factors for SARS-CoV-2 infection in patients presenting with symptoms in Shanghai, China: a multicentre, observational cohort study

The factors predicting pneumonia in COVID-19 patients: preliminary results of a university hospital in Turkey

Clinical Features of COVID-19 in Patients With Essential Hypertension and the Impacts of Renin-angiotensin-aldosterone System Inhibitors on the Prognosis of COVID-19 Patients

Performance of pneumonia severity index and CURB-65 in predicting 30-day mortality in patients with COVID-19

Distinct effects of asthma and COPD comorbidity on disease expression and outcome in patients with COVID-19

Previous and active tuberculosis increases risk of death and prolongs recovery in patients with COVID-19

Baseline electrolyte abnormalities would be related to poor prognosis in hospitalized coronavirus disease 2019 patients

Kidney function on admission predicts in-hospital mortality in COVID-19

Epidemiology of the first 100 cases of COVID-19 in Taiwan and its implications on outbreak control

Clinical features and potential risk factors for discerning the critical cases and predicting the outcome of patients with COVID-19

Allergic disorders and susceptibility to and severity of COVID-19: A nationwide cohort study

Incidence and Risk Factors of Deep Vein Thrombosis in Hospitalized COVID-19 Patients

Clinical characteristics of coronavirus disease 2019 (COVID-19) patients with hypertension on renin-angiotensin system inhibitors

Clinical characteristics and outcomes of COVID-19 hospitalized patients with diabetes in the United Kingdom: A retrospective single centre study

Low prevalence of bronchial asthma and chronic obstructive lung disease among intensive care unit patients with COVID-19

Increased mortality in patients with severe SARS-CoV-2 infection admitted within seven days of disease onset

A structural equation model to examine the clinical features of mild-to-moderate COVID-19: A multicenter Italian study

Presenting prevalence, characteristics and outcome of asthmatic patients with T2 diseases in hospitalized subjects with COVID-19 in Madrid, Spain

Characteristics and predictors of death among 4,035 consecutively hospitalized patients with COVID-19 in Spain

Characteristics and outcomes of asthmatic patients with COVID-19 pneumonia who require hospitalisation

Risk factors of fatal outcome in patients with COVID-19 pneumonia

Features of 20 133 UK patients in hospital with covid-19 using the ISARIC WHO Clinical Characterisation Protocol: prospective observational cohort study

Extent of pulmonary thromboembolic disease in patients with COVID-19 on CT: relationship with pulmonary parenchymal disease

Clinical features, ventilatory management, and outcome of ARDS caused by COVID-19 are similar to other causes of ARDS

Increased in-hospital mortality from COVID-19 in patients with schizophrenia

Asthma prevalence in patients with SARS-CoV-2 infection detected by RT-PCR not requiring hospitalization

SARS-CoV-2 Pneumonia in Hospitalized Asthmatic Patients Did Not Induce Severe Exacerbation

Delirium and encephalopathy in severe COVID-19: a cohort analysis of ICU patients

Early detection of deep vein thrombosis in patients with coronavirus disease 2019: who to screen and who not to with Doppler ultrasound?

Acute kidney injury in patients with SARS-CoV-2 infection

Features of Mild-to-Moderate COVID-19 Patients With Dysphonia

Characteristics and early outcomes of patients hospitalised for COVID-19 in North Zealand, Denmark

Impact of COVID-19 on liver function: results from an internal medicine unit in Northern Italy

Clinical course and outcomes of patients with asthma hospitalized for severe acute respiratory syndrome coronavirus 2pneumonia: A single-center, retrospective study

Adverse outcomes and mortality in users of non-steroidal anti-inflammatory drugs who tested positive for SARS-CoV-2: A Danish nationwide cohort study

Prognostic factors in patients admitted to an urban teaching hospital with COVID-19 infection

Comparative analysis between the use of renin-angiotensin system antagonists and clinical outcomes of hospitalized patients with COVID-19 respiratory infection

Clinical characteristics and predictors of outcomes of hospitalized patients with COVID-19 in a multi-ethnic London NHS Trust: a retrospective cohort study

Baseline Chronic Comorbidity and Mortality in Laboratory-Confirmed COVID-19 Cases: Results from the PRECOVID Study in Spain

Ethnicity and risk of death in patients hospitalised for COVID-19 infection in the UK: an observational cohort study in an urban catchment area

Characteristics and Mortality of Hospitalized Patients With COVID-19 in Iran: A National Retrospective Cohort Study

Mortality and pulmonary complications in patients undergoing surgery with perioperative SARS-CoV-2 infection: an international cohort study

Outcomes of COVID-19 in patients with CLL: a multicenter international experience

Remdesivir for Severe COVID-19 versus a Cohort Receiving Standard of Care

Global asthma prevalence in adults: findings from the cross-sectional world health survey

Respiratory health and disease in Europe: the new European Lung White Book

Adult Asthma Data: Prevalence Tables and Maps

Cerebrovascular disease is associated with the risk of mortality in coronavirus disease 2019

The association of hypertension with the severity and mortality of COVID-19 patients: Evidence based on adjusted effect estimates

Inhibitory effects of glycopyrronium, formoterol, and budesonide on coronavirus HCoV-229E replication and cytokine production by primary cultures of human nasal and tracheal epithelial cells

Montelukast, an Anti-asthmatic Drug, Inhibits Zika Virus Infection by Disrupting Viral Integrity

We would like to thank Xuan Liang, Peihua Zhang and Jian Wu (All are from Department of Epidemiology, College of Public Health, Zhengzhou University) for their kind help in searching articles and collecting data, and valuable suggestions for data analysis.